rivastigmine · Sandoz · NDA 020823, 021025, 022083
Exelon
Earliest generic entry, as listed · earliest of 3 marketed strengths
Open now
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- Generic approved · ANDA 215445, Yichang Humanwell · 022083-001Approved 23 Sep 2025Detected 25 Oct 2026Historical import
Products covered · 8
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 020823 · 003 · RLD · discontinued | capsule, oral | EQ 1.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | open |
| 020823 · 004 · RLD · discontinued | capsule, oral | EQ 3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | open |
| 020823 · 005 · RLD · discontinued | capsule, oral | EQ 4.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | open |
| 020823 · 006 · RLD · discontinued | capsule, oral | EQ 6MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | open |
| 021025 · 001 · RLD · discontinued | solution, oral | EQ 2MG BASE/ML | open |
| 022083 · 001 · RLD | film, extended release, transdermal | 4.6MG/24HR | open |
| 022083 · 002 · RLD | film, extended release, transdermal | 9.5MG/24HR | open |
| 022083 · 005 · RLD | film, extended release, transdermal | 13.3MG/24HR | open |